Multiparametric flow cytometric analysis in a breast cancer cell line (MCF‐7)

To investigate whether multiparameter flow cytometric analysis of solid tumor specimens, including gynecologic tumors, which were stained triply with phycoerythrin (PE), fluorescein isothiocyanate (FITC) and propidium iodide (PI), can be performed simultaneously without interference from normal diploid cell populations and spectral overlap on a standard flow cytometer.

[1]  P. van den Broek,et al.  Cell size, DNA, and cytokeratin analysis of human head and neck tumors by flow cytometry. , 1986, Cytometry.

[2]  C. Bloomfield,et al.  Use of surface marker analysis to predict outcome of adult acute myeloblastic leukemia. , 1986, Blood.

[3]  G. Mazzini,et al.  Cell cycle‐related proteins: a flow cytofluorometric study in human tumors , 1988, Biology of the cell.

[4]  D. W. Ross,et al.  Simultaneous paired analysis by flow cytometry of surface markers, cytoplasmic antigens, or oncogene expression with DNA content. , 1989, Cytometry.

[5]  C. Cornelisse,et al.  Nuclear distribution of the Ki-67 antigen during the cell cycle: comparison with growth fraction in human breast cancer cells. , 1989, Cancer research.

[6]  D. Visscher,et al.  Two-color multiparametric method for flow cytometric DNA analysis of carcinomas using staining for cytokeratin and leukocyte-common antigen. , 1989, Analytical and quantitative cytology and histology.

[7]  B. Czerniak,et al.  Flow cytometric measurements of DNA and other cell components in human tumors: a critical appraisal. , 1989, Human pathology.

[8]  V. Groppi,et al.  Cell cycle specific inhibitors. , 1989, Pharmacology & therapeutics.

[9]  T. Bauknecht,et al.  The expression of EGF receptors, EGF-like factors and c-myc in ovarian and cervical carcinomas and their potential clinical significance. , 1989, Anticancer research.

[10]  C. Osborne,et al.  Effects of c-myc overexpression on the growth characteristics of MCF-7 human breast cancer cells. , 1989, Oncogene.

[11]  T. Stephenson,et al.  C-myc oncogene product P62c-myc in ovarian mucinous neoplasms: immunohistochemical study correlated with malignancy. , 1989, Journal of clinical pathology.

[12]  D. Visscher,et al.  Multiparametric deoxyribonucleic acid and cell cycle analysis of breast carcinomas by flow cytometry. Clinicopathologic correlations. , 1990, Laboratory investigation; a journal of technical methods and pathology.

[13]  F. Spyratos,et al.  Flow cytometric analysis of DNA content and keratins by using CK7, CK8, CK18, CK19, and KL1 monoclonal antibodies in benign and malignant human breast tumors. , 1990, Cytometry.

[14]  C. Garrett,et al.  Protooncogene amplification and tumor ploidy in human ovarian neoplasms. , 1990, Human pathology.

[15]  R. Hawkins,et al.  Diabetes matters in primary care , 2002, International Journal of Integrated Care.

[16]  A. Begg,et al.  Cell kinetic analysis of mixed populations using three-color fluorescence flow cytometry. , 1991, Cytometry.

[17]  D. Visscher,et al.  Multiparametric evaluation of flow cytometric synthesis phase fraction determination in dual-labelled breast carcinomas. , 1991, Analytical and quantitative cytology and histology.

[18]  J. Giorgi,et al.  A gentle fixation and permeabilization method for combined cell surface and intracellular staining with improved precision in DNA quantification. , 1991, Cytometry.

[19]  T. Singleton,et al.  Clinical and pathologic significance of the c-erbB-2 (HER-2/neu) oncogene. , 1992, Pathology annual.

[20]  K. Toba,et al.  Improved staining method for the simultaneous flow cytofluorometric analysis of DNA content, S-phase fraction, and surface phenotype using single laser instrumentation. , 1992, Cytometry.

[21]  G. Landberg,et al.  Flow cytometric analysis of proliferation associated nuclear antigens using washless staining of unfixed cells. , 1992, Cytometry.

[22]  W. McGuire,et al.  Prognostic factors and treatment decisions in axillary-node-negative breast cancer. , 1992, The New England journal of medicine.

[23]  R. Leake,et al.  Epidermal growth factor receptor in normal ovaries and benign ovarian tumours. , 1992, European journal of obstetrics, gynecology, and reproductive biology.

[24]  Y. Usson,et al.  Intranuclear co-location of newly replicated DNA and PCNA by simultaneous immunofluorescent labelling and confocal microscopy in MCF-7 cells. , 1992, Journal of cell science.

[25]  I Schmid,et al.  Dead cell discrimination with 7-amino-actinomycin D in combination with dual color immunofluorescence in single laser flow cytometry. , 1992, Cytometry.

[26]  L. Wheeless,et al.  DNA cytometry consensus conference. , 1993, Cytometry.

[27]  M. Melamed,et al.  Consensus review of the clinical utility of DNA flow cytometry in colorectal cancer. , 1993, Cytometry.

[28]  C. Cox,et al.  Guidelines for implementation of clinical DNA cytometry. International Society for Analytical Cytology. , 1993, Cytometry.

[29]  M. Andreeff,et al.  Consensus review of the clinical utility of DNA flow cytometry in neoplastic hematopathology. , 1993, Cytometry.

[30]  L. Wheeless,et al.  Consensus review of the clinical utility of DNA cytometry in bladder cancer. Report of the DNA Cytometry Consensus Conference. , 1993, Cytometry.

[31]  Ellen,et al.  Prognostic significance of the Ki-67-associated proliferative antigen in aggressive non-Hodgkin's lymphomas: a prospective Southwest Oncology Group trial. , 1994, Blood.

[32]  J. Brooks,et al.  Genetic alterations in prostate cancer. , 1994, Cold Spring Harbor symposia on quantitative biology.

[33]  G. Fleuren,et al.  Simultaneous measurement of two cellular antigens and DNA using fluorescein-isothiocyanate, R-phycoerythrin, and propidium iodide on a standard FACScan. , 1994, Cytometry.

[34]  E. Wilander,et al.  Ki-67 immunostaining and DNA flow cytometry as prognostic factors in epithelial ovarian cancers. , 1994, Anticancer research.

[35]  P. van Damme,et al.  Expression of c-erbB-2, c-myc, and c-ras oncoproteins, insulin-like growth factor receptor I, and epidermal growth factor receptor in ovarian carcinoma. , 1994, Journal of clinical pathology.

[36]  P. Boracchi,et al.  Cell kinetics in human breast cancer: Comparison between the prognostic value of the cytofluorimetric S‐phase fraction and that of the antibodies to Ki‐67 and PCNA antigens detected by immunocytochemistry , 1994, International journal of cancer.

[37]  R. Hartsock,et al.  Assessing sequential oncogene amplification in human breast cancer. , 1995, Cytometry.

[38]  Preferred genetic evolutionary sequences in human breast cancer: a case study. , 1995, Cytometry.

[39]  H. Nguyen,et al.  Cytotoxic effects of adenovirus-mediated wild-type p53 protein expression in normal and tumor mammary epithelial cells. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

[40]  F. Waldman,et al.  ERBB-2 (HER2/neu) gene copy number, p185HER-2 overexpression, and intratumor heterogeneity in human breast cancer. , 1995, Cancer research.

[41]  F. Ramaekers,et al.  Three parameter flow cytometric analysis for simultaneous detection of cytokeratin, proliferation associated antigens and DNA content. , 1995, Cytometry.

[42]  S. Piantadosi,et al.  Poster 7: A Genetic Progression Model for Head and Neck Cancer: Implications for Field Cancerization , 1996, Cancer research.

[43]  L. Murphy,et al.  Analysis of human breast cancer nuclear proteins binding to the promoter elements of the c‐myc gene , 1996, Journal of cellular biochemistry.

[44]  F. Oesch,et al.  Prognostic significance of c-erB-2 mRNA in ovarian carcinoma. , 1996, Gynecologic oncology.

[45]  Nonisotopic quantitation of mRNA using a novel RNase protection assay: measurement of erbB-2 mRNA in tumor cell lines. , 1996, Analytical biochemistry.

[46]  N. Starr.  Pediatric gynecology urologic problems. , 1997, Clinical obstetrics and gynecology.

[47]  C. Yuan,et al.  Effects of tamoxifen and retinoic acid on cell growth and c-myc gene expression in human breast and cervical cancer cells. , 1997, Anticancer research.

[48]  H. Ozen.  Bladder cancer. , 1998, Current opinion in oncology.

[49]  P. Godeau.  [Consensus conference]. , 2000, La Revue de medecine interne.

[50]  F. Kern,et al.  MCF-7 breast cancer cells overexpressing transfectedc-erbB-2 have anin vitro growth advantage in estrogen-depleted conditions and reduced estrogen-dependence and tamoxifen-sensitivityin vivo , 1995, Breast Cancer Research and Treatment.

[51]  C. Cox,et al.  Guidelines for the implementation of clinical DNA cytometry , 2004, Breast Cancer Research and Treatment.